Join
Live feed
·
PRReleasevia Quantisnow
Inozyme Pharma Inc. logo

Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701

ByQuantisnow·Wall Street's wire, on your screen.
INZY· Inozyme Pharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INZY (Inozyme Pharma Inc.) and more on Quantisnow.